Department of Radiation Oncology, Osaka University Graduate School of Medicine, Suita, Japan
Osaka Heavy Ion Therapy Center, Osaka, Japan.
Anticancer Res. 2022 Jan;42(1):321-327. doi: 10.21873/anticanres.15488.
BACKGROUND/AIM: We evaluated the effectiveness and safety of stereotactic ablative radiotherapy (SABR) delivered using Cyberknife in patients with stage I non-small-cell lung cancer.
The clinical results of 153 patients with 161 lung cancers treated with CyberKnife between May 2014 and August 2020 at the Osaka University Hospital were retrospectively analyzed. The median age was 80 years (range=48-99 years). Nine patients (5.6%) had interstitial pneumonia. The median radiation dose was 52 Gy (range=40-70 Gy) in 4-10 fractions, and the median follow-up extended to 21.4 months (range=0-68.9 months).
The 2-year local control, progression-free, and overall survival rates were 91.9%, 61.7%, and 84.8%, respectively. Toxicities of grade ≥3 were observed in 13 (8.1%) patients; one patient with interstitial pneumonia developed grade 5 radiation pneumonitis and one patient developed grade 5 bronchopulmonary hemorrhage.
In patients with stage I non-small-cell lung cancer, SABR using Cyberknife was effective with acceptable toxicity.
背景/目的：我们评估了使用 Cyberknife 实施的立体定向消融放疗（SABR）在 I 期非小细胞肺癌患者中的有效性和安全性。
回顾性分析了 2014 年 5 月至 2020 年 8 月在大阪大学医院接受 CyberKnife 治疗的 153 例 161 例肺癌患者的临床结果。中位年龄为 80 岁（范围=48-99 岁）。9 例（5.6%）患者患有间质性肺炎。中位放疗剂量为 52 Gy（范围=40-70 Gy），分 4-10 次给予，中位随访时间延长至 21.4 个月（范围=0-68.9 个月）。
2 年局部控制、无进展和总生存率分别为 91.9%、61.7%和 84.8%。≥3 级毒性的发生率为 13 例（8.1%）；1 例间质性肺炎患者发生 5 级放射性肺炎，1 例患者发生 5 级支气管肺出血。
在 I 期非小细胞肺癌患者中，使用 Cyberknife 的 SABR 具有较好的疗效，且毒性可接受。
